Literature DB >> 22466811

Platelet glycoprotein IIIA PIA2 polymorphism is associated with ST elevation acute myocardial infarction in young Mexican population.

David Santiago-Germán1, Alfredo Leaños-Miranda, Ethel García-Latorre, Gabriela Borrayo-Sánchez, Abraham Majluf-Cruz, Irma Isordia-Salas.   

Abstract

Platelet membrane glycoprotein IIb/IIIa plays an important role in adhesion and platelet aggregation. Polymorphisms of genes in platelet activation and fibrinolysis have been associated with myocardial infarction (MI), however this has not been confirmed by others, and results are still controversial. The aim of this study was to determine the frequency distribution and association of polymorphism in the platelet glycoprotein GPIIIa PLA/A2 and the possible interaction with the 4G/5G in the plasminogen activator inhibitor genes with ST elevation acute myocardial infarction (STEAMI) in young Mexican subjects. A total of 254 unrelated patients with first STEAMI ≤45 years of age, who were admitted to a cardiovascular intense care unit and 254 healthy controls matched by age and gender were recruited from January 2006 and May 2011. The PIA1/A2 and 4G/5G polymorphism were determined in all participants by a PCR restriction based restriction endonuclease digestion. There was a difference in the PIA2 allele distribution between both groups (P = 0.001). Also, we found an increased percent of 4G allele in the group of patients compared to control group (P = 0.001). There was an increased risk for STEAMI in carries with the allele PIA2 and 4G (OR = 4.3, CI 95 % 1.7-6.5). The modifiable risk factors such: smoking, hypertension, family history of cardiovascular disease, and dyslipidemia were associated with myocardial infarction. This is the first study to evaluate the role of gene polymorphism in both the thrombotic and fibrinolytic pathways in young Mexican individuals with STEAMI and suggest a synergistic effect between PIA2 and 4G allele.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22466811     DOI: 10.1007/s11239-012-0714-x

Source DB:  PubMed          Journal:  J Thromb Thrombolysis        ISSN: 0929-5305            Impact factor:   2.300


  41 in total

1.  Increased platelet-collagen interaction associated with double homozygosity for receptor polymorphisms of platelet GPIa and GPIIIa.

Authors:  Luca Pontiggia; Riitta Lassila; Stephanie Pederiva; Hans-Rudolf Schmid; Mirjam Burger; Juerg H Beer
Journal:  Arterioscler Thromb Vasc Biol       Date:  2002-12-01       Impact factor: 8.311

2.  PIA1/A2 polymorphism of the platelet glycoprotein receptor IIb/IIIIa and its correlation with myocardial infarction: an appraisal.

Authors:  Viroj Wiwanitkit
Journal:  Clin Appl Thromb Hemost       Date:  2006-01       Impact factor: 2.389

3.  Plasminogen activator inhibitor type 1 (PAI-1) and platelet glycoprotein IIIa (PGIIIa) polymorphisms in young Asian Indians with acute myocardial infarction.

Authors:  R J Pegoraro; N Ranjith
Journal:  Cardiovasc J S Afr       Date:  2005 Sep-Oct

4.  Glycoprotein IIIa polymorphism and risk of myocardial infarction.

Authors:  N J Samani; D Lodwick
Journal:  Cardiovasc Res       Date:  1997-03       Impact factor: 10.787

5.  Prospective analysis after coronary-artery bypass grafting: platelet GP IIIa polymorphism (HPA-1b/PIA2) is a risk factor for bypass occlusion, myocardial infarction, and death.

Authors:  R B Zotz; M Klein; H P Dauben; C Moser; E Gams; R E Scharf
Journal:  Thromb Haemost       Date:  2000-03       Impact factor: 5.249

6.  Association of the GPIa C807T and GPIIIa PlA1/A2 polymorphisms with premature myocardial infarction in men.

Authors:  G Benze; J Heinrich; H Schulte; S Rust; U Nowak-Göttl; M-C Tataru; E Köhler; G Assmann; R Junker
Journal:  Eur Heart J       Date:  2002-02       Impact factor: 29.983

7.  Acute myocardial infarction in the young--The University of Michigan experience.

Authors:  Michele Doughty; Raj Mehta; David Bruckman; Sugata Das; Dean Karavite; Thomas Tsai; Kim Eagle
Journal:  Am Heart J       Date:  2002-01       Impact factor: 4.749

8.  Association of the plasminogen activator inhibitor-1 gene 4G/5G polymorphism with ST elevation acute myocardial infarction in young patients.

Authors:  Irma Isordia-Salas; Alfredo Leaños-Miranda; Irma M Sainz; Elba Reyes-Maldonado; Gabriela Borrayo-Sánchez
Journal:  Rev Esp Cardiol       Date:  2009-04       Impact factor: 4.753

9.  Platelet glycoprotein IIb/IIIa genetic polymorphism is associated with plasma fibrinogen levels in myocardial infarction patients. The REGICOR Investigators.

Authors:  M Sentí; C Aubó; M Bosch; M Pavesi; A Pena; R Masiá; J Marrugat
Journal:  Clin Biochem       Date:  1998-11       Impact factor: 3.281

10.  Genetic variation of the platelet- surface integrin GPIIb-IIIa (PIA1/A2-SNP) shows a high association with Type 2 diabetes mellitus.

Authors:  D Tschoepe; B Menart; P Ferber; C Altmann; M Haude; B Haastert; P Roesen
Journal:  Diabetologia       Date:  2003-06-21       Impact factor: 10.122

View more
  3 in total

1.  Platelet glycoprotein IIIA PIA1/A2 polymorphism in young patients with ST elevation myocardial infarction and idiopathic ischemic stroke.

Authors:  Blanca Elsa Rivera-García; Juan Carlos Esparza-García; Jose Luis Aceves-Chimal; Alfredo Leaños-Miranda; Abraham Majluf-Cruz; Irma Isordia-Salas
Journal:  Mol Cell Biochem       Date:  2013-09-05       Impact factor: 3.396

2.  The PlA1/A2 polymorphism of glycoprotein IIIa as a risk factor for myocardial infarction: a meta-analysis.

Authors:  Christopher N Floyd; Agnesa Mustafa; Albert Ferro
Journal:  PLoS One       Date:  2014-07-02       Impact factor: 3.240

3.  Genetic Polymorphisms Associated with Thrombotic Disease Comparison of Two Territories: Myocardial Infarction and Ischemic Stroke.

Authors:  Irma Isordia-Salas; Manuel Martínez-Marino; Paolo Alberti-Minutti; María Tania Ricardo-Moreno; Ricardo Castro-Calvo; David Santiago-Germán; José Antonio Alvarado-Moreno; Cristian Calleja-Carreño; Jesús Hernández-Juárez; Alfredo Leaños-Miranda; Abraham Majluf-Cruz
Journal:  Dis Markers       Date:  2019-10-30       Impact factor: 3.434

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.